IgG antibody levels against the Ebola surface glycoprotein were measured in serum at baseline and at week 1 and months 1, 6, and 12 with the use of the Filovirus Animal Nonclinical Group (FANG) assay (Section 3 in the Supplementary Appendix ). Antibody levels were also measured in plasma at days 3, 10, and 14 in 24 participants for whom rVSVĪG-ZEBOV-GP shedding was measured on those days.
A participant was considered to have a positive vaccine response at a follow-up visit if the log10 titer was increased by a factor of 4 or more from the baseline value (see Section 3 in theSupplementary Appendix ) and if the participant had not had an elevated titer at baseline. All the laboratory measurements were performed in Liberia. At the time of the trial, there were no facilities in the country for measuring T-cell responses.
A participant was considered to have a positive vaccine response at a follow-up visit if the log10 titer was increased by a factor of 4 or more from the baseline value (see Section 3 in the
